| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Cristina Rusu | |
| Lucian Miron | |||
| Teodora Alexa-Stratulat | |||
| Bogdan Gafton | |||
| Mihai Vasile Marinca | |||
| Vlad-Adrian Afrăsânie | |||
| Anca Maria Adavidoaiei | |||
| Marius Păduraru | |||
| P2860 | cites work | Raf family kinases: old dogs have learned new tricks | Q24316181 |
| Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab | Q24600031 | ||
| PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis | Q26992267 | ||
| Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer | Q27027648 | ||
| Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis | Q36175906 | ||
| Systemic therapy for metastatic colorectal cancer: current options, current evidence | Q36186140 | ||
| Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part II. The utility of microsatellite instability testing | Q36734614 | ||
| Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial | Q36977022 | ||
| PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer | Q37137091 | ||
| Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer | Q37287501 | ||
| Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. | Q37360712 | ||
| A meta-analysis of MSI frequency and race in colorectal cancer | Q37376333 | ||
| Spectrum of K ras mutations in Pakistani colorectal cancer patients | Q37600029 | ||
| Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis | Q38054578 | ||
| Lynch syndrome in the 21st century: clinical perspectives | Q38557159 | ||
| RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data. | Q38659782 | ||
| Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer | Q39214250 | ||
| Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor | Q40409619 | ||
| Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. | Q40933980 | ||
| Molecular profiling of metastatic colorectal tumors using next-generation sequencing: a single-institution experience | Q41091941 | ||
| KRAS gene mutations - prognostic factor in colorectal cancer? | Q41273625 | ||
| KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial | Q43250046 | ||
| Current and future biomarkers in colorectal cancer | Q43492228 | ||
| PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. | Q43562170 | ||
| KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer | Q44246197 | ||
| Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. | Q44995693 | ||
| Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab | Q45102101 | ||
| Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. | Q45938699 | ||
| Clinical Predictors for KRAS Codon 13 Mutations in Patients With Colorectal Cancer. | Q47421727 | ||
| BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives | Q47767987 | ||
| Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer | Q49887005 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 | Q27851532 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer | Q27851787 | ||
| HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients | Q27852057 | ||
| Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes | Q27852062 | ||
| BRAFV600E mutation and its association with clinicopathological features of colorectal cancer: a systematic review and meta-analysis | Q27852942 | ||
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis | Q27853129 | ||
| Global cancer statistics, 2002 | Q27860562 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics | Q28253670 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| HER 2/neu protein expression in colorectal cancer | Q33242725 | ||
| HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression | Q33690070 | ||
| Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 | ||
| HER-2 overexpression and survival in colorectal cancer: a meta-analysis | Q33979049 | ||
| Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials | Q34263478 | ||
| FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. | Q34492429 | ||
| HER2/neu testing in primary colorectal carcinoma | Q34499615 | ||
| BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer | Q34621860 | ||
| Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer | Q34628085 | ||
| Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. | Q34658519 | ||
| The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies: a meta-analysis | Q34776118 | ||
| Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine | Q35067570 | ||
| KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer | Q35098287 | ||
| Microsatellite instability and the clinicopathological features of sporadic colorectal cancer | Q35363901 | ||
| BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing | Q35446668 | ||
| BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum | Q35596687 | ||
| An overview of colorectal cancer survival rates and prognosis in Asia | Q35906947 | ||
| BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis | Q35962621 | ||
| Microsatellite instability testing and its role in the management of colorectal cancer. | Q36124008 | ||
| Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. | Q50888998 | ||
| Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. | Q51552580 | ||
| Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. | Q51597972 | ||
| Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. | Q51776004 | ||
| Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. | Q53305712 | ||
| Somatic mutations of K-ras and BRAF in Thai colorectal cancer and their prognostic value. | Q54266461 | ||
| Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. | Q54310262 | ||
| Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. | Q54962247 | ||
| Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study | Q57152185 | ||
| Molecular characteristics of colorectal cancer in a Middle Eastern population in a single institution | Q58803324 | ||
| Prevalence of ras gene mutations in human colorectal cancers | Q59088716 | ||
| FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer | Q59218920 | ||
| K-ras gene mutations in adenomas and carcinomas of the colon | Q67510951 | ||
| Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type | Q70753013 | ||
| The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer | Q73212054 | ||
| Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival | Q77432075 | ||
| Systemic treatment of colorectal cancer | Q81253030 | ||
| Strategy in clinical practice for classification of unselected colorectal tumours based on mismatch repair deficiency | Q81295182 | ||
| Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome | Q81527911 | ||
| [Identification of K-RAS mutations in colorectal cancer patients in Israel] | Q84374981 | ||
| Mutant KRAS codon 12 and 13 alleles in patients with metastatic colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab | Q85537558 | ||
| Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia | Q87537926 | ||
| Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study | Q92502573 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported | Q19125045 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | colorectal cancer | Q188874 |
| microsatellite | Q265193 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 265-274 | |
| P577 | publication date | 2019-09-24 | |
| P1433 | published in | Radiology and Oncology | Q26842803 |
| P1476 | title | KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer - practical implications for the clinician | |
| P478 | volume | 53 |
Search more.